MedPath

Lorazepam

Generic Name
Lorazepam
Brand Names
Ativan, Loreev
Drug Type
Small Molecule
Chemical Formula
C15H10Cl2N2O2
CAS Number
846-49-1
Unique Ingredient Identifier
O26FZP769L
Background

Lorazepam is a short-acting and rapidly cleared benzodiazepine used commonly as a sedative and anxiolytic. It was developed by DJ Richards, presented and marketed initially by Wyeth Pharmaceuticals in the USA in 1977. The first historic FDA label approval is reported in 1985 by the company Mutual Pharm.

Indication

Lorazepam is FDA-approved for the short-term relief of anxiety symptoms related to anxiety disorders and anxiety associated with depressive symptoms such as anxiety-associated insomnia. It is as well used as an anesthesia premedication in adults to relieve anxiety or to produce sedation/amnesia and for the treatment of status epilepticus.

Some off-label indications of lorazepam include rapid tranquilization of an agitated patient, alcohol withdrawal delirium, alcohol withdrawal syndrome, muscle spasms, insomnia, panic disorder, delirium, chemotherapy-associated anticipatory nausea and vomiting, and psychogenic catatonia.

Associated Conditions
Agitation, Alcohol Withdrawal Delirium, Alcohol Withdrawal Syndrome, Anxiety, Anxiety Disorders, Chemotherapy-Induced Nausea and Vomiting, Delirium, Insomnia, Muscle Spasms, Panic Disorder, Psychogenic Catatonia, Status Epilepticus
Associated Therapies
Anesthetic premedication therapy
Clinical Trials
Related News

Haloperidol and Lorazepam in Controlling Symptoms of Persistent Agitated Delirium in Patients With Advanced Cancer Undergoing Palliative Care

Phase 2
Active, not recruiting
Conditions
Locally Advanced Malignant Neoplasm
Delirium
Recurrent Malignant Neoplasm
Metastatic Malignant Neoplasm
Interventions
Other: Placebo
Other: Quality-of-Life Assessment
Other: Questionnaire Administration
First Posted Date
2018-11-16
Last Posted Date
2025-01-10
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
110
Registration Number
NCT03743649
Locations
🇺🇸

M D Anderson Cancer Center, Houston, Texas, United States

🇺🇸

Virginia Commonwealth University/Massey Cancer Center, Richmond, Virginia, United States

🇧🇷

Hosptial de Cancer de Barretos, Barretos, Sao Paulo, Brazil

Post Operative Pain Control After Pediatric Hip Surgery

Not Applicable
Terminated
Conditions
Post Operative Pain Control
Hip Surgery
Interventions
Procedure: Lumbar Plexus Catheter
Procedure: Lumbar Epidural Catheter
Procedure: Patient Controlled Analgesia
First Posted Date
2018-02-19
Last Posted Date
2021-11-02
Lead Sponsor
Seattle Children's Hospital
Target Recruit Count
42
Registration Number
NCT03435692

Psilocybin for Treatment of Obsessive Compulsive Disorder

Phase 1
Completed
Conditions
Obsessive-compulsive Disorder (OCD)
Interventions
First Posted Date
2017-10-04
Last Posted Date
2024-08-30
Lead Sponsor
University of Arizona
Target Recruit Count
15
Registration Number
NCT03300947
Locations
🇺🇸

University of Arizona, Tucson, Arizona, United States

Assessment of Valproate on Ethanol Withdrawal

Phase 4
Conditions
Trauma
Alcohol Use Disorder
Alcohol Dependence
Alcohol Withdrawal Syndrome
Heavy Drinking
Interventions
First Posted Date
2017-08-01
Last Posted Date
2017-08-01
Lead Sponsor
CAMC Health System
Target Recruit Count
210
Registration Number
NCT03235531
Locations
🇺🇸

Charleston Area Medical Center, Charleston, West Virginia, United States

🇺🇸

Charleston Area Medical Center, General Hospital, Level 1 Trauma Center, Charleston, West Virginia, United States

Effect of A Single Dose of Lorazepam on Salivary Cortisol Response in Children Undergoing Digestive Endoscopy:

Phase 2
Completed
Conditions
Anxiety
Interventions
Other: Placebo
First Posted Date
2017-06-08
Last Posted Date
2018-09-05
Lead Sponsor
St. Justine's Hospital
Target Recruit Count
98
Registration Number
NCT03180632
Locations
🇨🇦

CHU Sainte-Justine, Montréal, Quebec, Canada

Treatment of Adolescent Antimuscarinic (Anticholinergic) Toxidrome

Phase 4
Completed
Conditions
Anticholinergics Toxicity
Interventions
First Posted Date
2017-03-27
Last Posted Date
2021-08-23
Lead Sponsor
University of Colorado, Denver
Target Recruit Count
19
Registration Number
NCT03090620
Locations
🇺🇸

University of Colorado Anschutz Medical Campus, Children's Hospital Colorado, Aurora, Colorado, United States

A Study to Assess the Efficacy and Safety of Brivaracetam as Treatment for Increased Seizure Activity in an Epilepsy Monitoring Unit Setting

Phase 2
Completed
Conditions
Epilepsy
Interventions
First Posted Date
2017-01-13
Last Posted Date
2020-12-16
Lead Sponsor
UCB Biopharma S.P.R.L.
Target Recruit Count
46
Registration Number
NCT03021018
Locations
🇺🇸

Ep0087 108, Birmingham, Alabama, United States

🇺🇸

Ep0087 117, Tucson, Arizona, United States

🇺🇸

Ep0087 112, Orlando, Florida, United States

and more 11 locations

Analgesia for Endometrial Scratching

Not Applicable
Completed
Conditions
Infertility
Subfertility
Interventions
Drug: Placebo
First Posted Date
2016-08-11
Last Posted Date
2018-05-08
Lead Sponsor
University of Sao Paulo
Target Recruit Count
150
Registration Number
NCT02863614

PF-06372865 in Subjects With Photosensitive Epilepsy

Phase 2
Completed
Conditions
Reflex Epilepsy, Photosensitive
Interventions
Drug: Placebo
First Posted Date
2015-09-30
Last Posted Date
2018-03-14
Lead Sponsor
Pfizer
Target Recruit Count
7
Registration Number
NCT02564029
Locations
🇺🇸

Consultants in Epilepsy & Neurology, PLLC, Boise, Idaho, United States

🇺🇸

Hospital of the Univ of PA Pharmacy Service, Philadelphia, Pennsylvania, United States

🇺🇸

Thomas Jefferson University Hospital EEG lab, Philadelphia, Pennsylvania, United States

and more 13 locations

Catatonia in Nodding Syndrome and Lorazepam Treatment

Phase 1
Completed
Conditions
Catatonia
Nodding Syndrome
Interventions
First Posted Date
2015-06-03
Last Posted Date
2015-06-03
Lead Sponsor
Makerere University
Target Recruit Count
16
Registration Number
NCT02462109
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy